It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...
Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...
The following contains links to social media websites including Bluesky, X, TikTok, Instagram, Facebook, and LinkedIn. "Make ...
Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...
A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...
A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.
Although reports of vision problems with weight loss drugs are still rare, researchers say there is cause for concern because ...
These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...
When Trova Wine and Market shut its doors last month after nearly five years in Dallas, owner Michelle Bonds pointed to an unexpected reason for closure: GLP-1 weight loss drugs like Ozempic.